Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/24/2026

1. INTC
2. DECK
3. AMD
4. META
5. INFY
6. RNG
7. SPY
8. TMUS
9. UNP
10. GOOGL

Go back to Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance
(NASDAQ: ABVX) Delayed: 125.70 -5.46 (4.16%)
Previous Close $131.16    52 Week High $ 
Open $133.15    52 Week Low $ 
Day High $133.23    P/E N/A 
Day Low $125.68    EPS $ 
Volume 950,960       

(NASDAQ: ABVX) Delayed: 125.70 -5.46 (4.16%)
Previous Close $131.16    52 Week High $ 
Open $133.15    52 Week Low $ 
Day High $133.23    P/E N/A 
Day Low $125.68    EPS $ 
Volume 950,960